Robert Harrington to Endpoint Determination
This is a "connection" page, showing publications Robert Harrington has written about Endpoint Determination.
Connection Strength
0.669
-
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 01; 170(3):e59-62.
Score: 0.438
-
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. J Am Coll Cardiol. 2016 11 29; 68(21):2385-2387.
Score: 0.133
-
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002 Jan 22; 105(3):322-7.
Score: 0.048
-
Planning and Conducting the ISCHEMIA Trial. Circulation. 2018 10 02; 138(14):1384-1386.
Score: 0.038
-
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19; 359(9302):189-98.
Score: 0.012